What do idiopathic pulmonary fibrosis, AI and aging have in common? One answer has emerged from the results of a recent study capturing attention across science and medicine. This study has shown that a drug intended to treat idiopathic pulmonary fibrosis (IPF) also shifts several blood-based measures of biological aging1. And, the drug was discovered with AI.2
Rentosertib, the drug in question, offers an unusual test case: it’s an AI-discovered drug which was developed for an age-associated disease. In a small sub-study of a larger clinical trial, patients who took rentosertib had a consistent decline in six blood-based aging clocks.…
